The endothelin system in pulmonary and renal vasculopathy: Les liaisons dangereuses

European Respiratory Review

Volumn 18, Issue 114, 2009, Pages 260-271

  Vachiery J L ^a   Davenport, A ^b  

^a ERASME HOSPITAL   (Belgium)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Chronic kidney disease; Endothelin; Pulmonary hypertension

Indexed keywords

AMBRISENTAN; BOSENTAN; CYCLIC GMP DERIVATIVE; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; ILOPROST; IMATINIB; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; RIOCIGUAT; SILDENAFIL; SITAXSENTAN; TADALAFIL; TAK 044; TEZOSENTAN; UNCLASSIFIED DRUG; UNIPROST;

ADD ON THERAPY; CARDIOPULMONARY INSUFFICIENCY; CLINICAL TRIAL; CONTINUOUS INFUSION; DIZZINESS; DRUG MECHANISM; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FLUSHING; HEADACHE; HUMAN; KIDNEY PARENCHYMA; LIVER FUNCTION; LIVER TOXICITY; LUNG PARENCHYMA; NAUSEA; NONHUMAN; NOSE CONGESTION; PERIPHERAL EDEMA; PHYSIOLOGY; PROTEIN EXPRESSION; PROTHROMBIN TIME; PULMONARY HYPERTENSION; RENAL VASCULOPATHY; RENOVASCULAR DISEASE; REVIEW; SIDE EFFECT; SYNCOPE;

ENDOTHELIN-1; HUMANS; HYPERTENSION, PULMONARY; HYPERTENSION, RENAL; RECEPTOR, ENDOTHELIN A;

EID: 73449127260     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00005709     Document Type: Review

References (81)

1. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989; 86: 2863-2867.
2. Haynes WG, Webb DJ. The endothelin family of peptides: local hormones with diverse roles in health and disease? Clin Sci (Lond) 1993; 84: 485-500.
3. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.
4. Chua BH, Krebs CJ, Chua CC, et al. Endothelin stimulates protein synthesis in smooth muscle cells. Am J Physiol 1992; 262: E412-E416.
5. Kohan DE. Endothelins in the normal and diseased kidney. Am J Kidney Dis 1997; 29: 2-26.
6. Emoto N, Yanagisawa M. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem 1995; 270: 15262-15268.
7. Davenport AP, Maguire JJ. Endothelin. Handb Exp Pharmacol 2006; 295-329.
8. Russell FD, Davenport AP. Secretory pathways in endothelin synthesis. Br J Pharmacol 1999; 126: 391-398.
9. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994; 344: 852-854. 10 Russell FD, Skepper JN, Davenport AP. Human endothelial cell storage granules: a novel intracellular site for isoforms of the endothelin-converting enzyme. Circ Res 1998; 83: 314-321.
10. Takuwa Y, Kasuya Y, Takuwa N, et al. Endothelin receptor is coupled to phospholipase C via a pertussis toxin-insensitive guanine nucleotide-binding regulatory protein in vascular smooth muscle cells. J Clin Invest 1990; 85: 653-658.
11. Hosoda K, Nakao K, Tamura N, et al. Organization, structure, chromosomal assignment, and expression of the gene encoding the human endothelin-A receptor. J Biol Chem 1992; 267: 18797-18804.
12. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990; 348: 732-735.
13. Arai H, Hori S, Aramori I, et al. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348: 730-732.
14. Hirata Y, Emori T, Eguchi S, et al. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 1993; 91: 1367-1373.
15. Fukuroda T, Fujikawa T, Ozaki S, et al. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 1994; 199: 1461-1465.
16. Plumpton C, Ferro CJ, Haynes WG, et al. The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044. Br J Pharmacol 1996; 119: 311-314.
17. Gariepy CE, Ohuchi T, Williams SC, et al. Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest 2000; 105: 925-933.
18. 18F- Endothelin-1, a positron emission tomography (PET) radioligand for the endothelin receptor system: radiosynthesis and in vivo imaging using microPET. Clin Sci (Lond) 2002; 103: Suppl. 48, 4S-8S.
19. Gasic S, Wagner OF, Vierhapper H, et al. Regional hemodynamic effects and clearance of endothelin-1 in humans: renal and peripheral tissues may contribute to the overall disposal of the peptide. J Cardiovasc Pharmacol 1992; 19: 176-180.
20. Neuhofer W, Pittrow D. Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence. Eur J Clin Invest 2009; 39: Suppl. 2, 50-67.
21. Karet FE, Kuc RE, Davenport AP. Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney. Kidney Int 1993; 44: 36-42.
22. Karet FE, Davenport AP. Localization of endothelin peptides in human kidney. Kidney Int 1996; 49: 382-387.
23. Pernow J, Franco-Cereceda A, Matran R, et al. Effect of endothelin-1 on regional vascular resistances in the pig. J Cardiovasc Pharmacol 1989; 13: Suppl. 5, S205-S206.
24. Denton KM, Anderson WP. Vascular actions of endothelin in the rabbit kidney. Clin Exp Pharmacol Physiol 1990; 17: 861-872.
25. Voelkel NF, Quaife RA, Leinwand LA, et al. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 2006; 114: 1883-1891.
26. Thenappan T, Shah SJ, Rich S, et al. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 2007; 30: 1103-1110.
27. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119: 2250-2294.
28. Rubens C, Ewert R, Halank M, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001; 120: 1562-1569.
29. Yoshibayashi M, Nishioka K, Nakao K, et al. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. Circulation 1991; 84: 2280-2285.
30. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. Engl J Med 1993; 328: 1732-1739.
31. Lutz J, Gorenflo M, Habighorst M, et al. Endothelin-1- and endothelin-receptors in lung biopsies of patients with pulmonary hypertension due to congenital heart disease. Clin Chem Lab Med 1999; 37: 423-428.
32. Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991; 114: 464-469.
33. Davie N, Haleen SJ, Upton PD, et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002; 165: 398-405.
34. Koyama H, Tabata T, Nishzawa Y, et al. Plasma endothelin levels in patients with uraemia. Lancet 1989; 1: 991-992.
35. Goddard J, Johnston NR, Cumming AD, et al. Fractional urinary excretion of endothelin-1 is reduced by acute ETB receptor blockade. Am J Physiol Renal Physiol 2007; 293: F1433-F1438.
36. Orisio S, Benigni A, Bruzzi I, et al. Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 1993; 43: 354-358.
37. Zoccali C, Leonardis D, Parlongo S, et al. Urinary and plasma endothelin 1 in essential hypertension and in hypertension secondary to renoparenchymal disease. Nephrol Dial Transplant 1995; 10: 1320-1323.
38. Kanai H, Okuda S, Kiyama S, et al. Effects of endothelin and angiotensin II on renal hemodynamics in experimental mesangial proliferative nephritis. Nephron 1993; 64: 609-614.
39. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000; 102: 2434-2440.
40. Opocensky M, Kramer HJ, Backer A, et al. Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension. Hypertension 2006; 48: 965-971.
41. Goddard J, Johnston NR, Hand MF, et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 2004; 109: 1186-1193.
42. Cedergreen JC, Markin CJ, Wahba IM. Prevalence of chronic kidney disease in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2009; 179: A4864.
43. Davenport AP. International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev 2002; 54: 219-226.
44. Dhaun N, Pollock DM, Goddard J, et al. Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol Sci 2007; 28: 573-579.
45. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-1123.
46. Galie N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 529-535.
47. Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010-3019.
48. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
49. Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114: 48-54.
50. Galie N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-2100.
51. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169: 441-447.
52. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47: 2049-2056.
53. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with firstline bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25: 244-249.
54. Sitbon O, McLaughlin VV, Badesch DB, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 2005; 60: 1025-1030.
55. Provencher S, Sitbon O, Humbert M, et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006; 27: 589-595.
56. Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 170: 1212-1217.
57. Degano B, Yaici A, Le Pavec J, et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J 2009; 33: 92-98.
58. Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004; 24: 1007-1010.
59. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006; 28: 691-694.
60. Hoeper MM, Seyfarth HJ, Hoeffken G, et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J 2007; 30: 1096-1102.
61. Wu C, Chan MF, Stavros F, et al. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med Chem 1997; 40: 1690-1697.
62. Benza RL, Barst RJ, Galie N, et al. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. Chest 2008; 134: 775-782.
63. Langleben D, Cacoub P. A review of STRIDE- 2 and STRIDE-2X: the case for selective endothelin receptor blockade. Eur J Clin Invest 2009; 39: 27-31.
64. Galie N, Naeije R, Burgess G, et al. 3-year survival of patients treated with sitaxentan sodium (Thelin®) for pulmonary arterial hypertension. Eur Heart J 2009; 30: 262.
65. Benza RL, Mehta S, Keogh A, et al. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J Heart Lung Transplant 2007; 26: 63-69.
66. Girgis RE, Frost AE, Hill NS, et al. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis 2007; 66: 1467-1472.
67. Davie NJ, Schermuly RT, Weissmann N, et al. The science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies. Eur J Clin Invest 2009; 39: Suppl. 2, 38-49.
68. Vatter H, Seifert V. Ambrisentan, a non-peptide endothelin receptor antagonist. Cardiovasc Drug Rev 2006; 24: 63-76.
69. Oudiz RJ. Ambrisentan therapy in patients with pulmonary arterial hypertension: 2-year outcome. Chest 2008; 134: S4001.
70. McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 2009; 135: 122-129.
71. Seyfarth HJ, Pankau H, Hammerschmidt S, et al. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy. Chest 2005; 128: 709-713.
72. Hoeper MM, Taha N, Bekjarova A, et al. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 2003; 22: 330-334.
73. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24: 353-359.
74. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174: 1257-1263.
75. Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 2007; 29: 469-475.
76. Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-2903.
77. Faruqi S, Fathi H, Morice AH. Combination of sitaxentan and tadalafil for idiopathic pulmonary arterial hypertension following relapse on bosentan. Int J Cardiol 2008 [Epub ahead of print DOI: 10.1016/j.ijcard.2008.12. 065].
78. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
79. Dhaun N, Ferro CJ, Davenport AP, et al. Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. Nephrol Dial Transplant 2007; 22: 3228-3234.
80. Pedersen EB, Thomsen IM, Fjordside LS. Effect of BQ-123, an endothelin antagonist, on renal hemodynamics, tubular function, vasoactive hormones, and blood pressure in healthy humans: a dose response study. Am J Hypertens 2005; 18: 1578-1585.
81. Dhaun N, Macintyre IM, Melville V, et al. Blood pressureindependent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. Hypertension 2009; 54: 113-119.